Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President | August 12, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 253,390 |
Reported balance
After 2026-08-12 transaction · row 1
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 146,403 · Balance 253,390 F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 13, 2026 20:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 146,403 | $17.51 | $2,563,516.53 |
DisclosureSEC source: 0001628280-26-056757 · wk-form4_1786652518.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,390 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 15 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,760 Underlying: Class A Common Stock · 35,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F9 · derivative.expiration_date: On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 17,976 | $13.30 | $239,080.80 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 10 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,793 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 9 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 366,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 14 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 366,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 23,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 13 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,634 Underlying: Class A Common Stock · 23,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 94,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On March 3, 2025, the reporting person was granted 94,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 45,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 12 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,872 Underlying: Class A Common Stock · 45,871 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · derivative · entry 11 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 36,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 183,853 | $13.31 | $2,447,083.43 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 8 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,889 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 366,972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 7 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,796 | $13.31 | $157,004.76 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 6 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,770 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 23,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 22,982 | $13.31 | $305,890.42 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,022 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 18,502 | $13.31 | $246,261.62 |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,133 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015235 · wk-form4_1772746235.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:28 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 65,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013890 · wk-form4_1772573314.xml · derivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,359 Underlying: Class A Common Stock · 65,359 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:28 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 65,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013890 · wk-form4_1772573314.xml · derivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,359 Underlying: Class A Common Stock · 65,359 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option (Right to Buy) · Derivative | 95,525 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · derivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 95,525 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,331 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · derivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 36,331 shares Expires 2028-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 131,856 | $11.92 | $1,571,723.52 |
DisclosureSEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · nonDerivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,403 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.02 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 95,525 | $2.75 | $262,693.75 |
DisclosureSEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,331 | $2.75 | $99,910.25 |
DisclosureSEC source: 0001628280-25-052413 · wk-form4_1763158428.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 25, 2025 20:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 6,340 | $9.50 | $60,230.00 |
DisclosureSEC source: 0001738061-25-000004 · wk-form4_1756153648.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,403 F2 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.51 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 22, 2025 Filed Aug 25, 2025 20:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 114,492 | $9.66 | $1,105,992.72 |
DisclosureSEC source: 0001738061-25-000004 · wk-form4_1756153648.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,743 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.75 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 20:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 71,694 | $9.29 | $666,037.26 |
DisclosureSEC source: 0001723128-25-000052 · wk-form4_1755289907.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,235 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.16 to $9.41 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 20:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 50,000 | $9.04 | $452,000.00 |
DisclosureSEC source: 0001723128-25-000050 · wk-form4_1755117633.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,929 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.07 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:16 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 49,140 | $7.58 | $372,481.20 |
DisclosureSEC source: 0001628280-25-026513 · wk-form4_1747685776.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,929 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 35,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 14 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,640 Underlying: Class A Common Stock · 35,879 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F11 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F11 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 18,353 | $8.84 | $162,240.52 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 8 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,069 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 35,879 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 7 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 94,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 13 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,178 Underlying: Class A Common Stock · 94,178 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F10 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. F10 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 188,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 12 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,356 Underlying: Class A Common Stock · 188,356 shares Expires not disclosed F8 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 94,178 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units will be deemed earned and vested when settled into shares of Class A Common Stock shortly after February 28, 2028, the last day of the performance period. F9 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 94,178 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units will be deemed earned and vested when settled into shares of Class A Common Stock shortly after February 28, 2028, the last day of the performance period. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 144,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 11 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 144,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 45,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 10 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,743 Underlying: Class A Common Stock · 45,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 9 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,232 Underlying: Class A Common Stock · 36,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 74,131 | $8.76 | $649,387.56 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 6 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,543 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 144,928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 5 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 23,464 | $8.76 | $205,544.64 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 4 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,746 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 18,533 | $8.76 | $162,349.08 |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,338 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:58 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 28,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010113 · wk-form4_1741132675.xml · derivative · entry 3 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 28,958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal payments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal payments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:58 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 10,985 | $8.67 | $95,239.95 |
DisclosureSEC source: 0001628280-25-010113 · wk-form4_1741132675.xml · nonDerivative · entry 2 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,639 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:58 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 28,958 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010113 · wk-form4_1741132675.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 100,000 | $7.75 | $775,000.00 |
DisclosureSEC source: 0001628280-24-037557 · wk-form4_1723839453.xml · nonDerivative · entry 1 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,666 F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $7.84 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 287,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · derivative · entry 11 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,038 Underlying: Class A Common Stock · 287,038 shares Expires not disclosed F8 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. F9 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 143,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · derivative · entry 10 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,519 Underlying: Class A Common Stock · 143,519 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: The restricted stock units vest in four equal installments beginning on March 4, 2025. F7 · derivative.expiration_date: The restricted stock units vest in four equal installments beginning on March 4, 2025. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 45,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · derivative · entry 9 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,615 Underlying: Class A Common Stock · 45,871 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:35 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 36,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008945 · wk-form4_1709674499.xml · derivative · entry 8 Shah Nikita · CIK 0001738061 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,464 Underlying: Class A Common Stock · 36,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.